Alkem Labs recommends ₹10 dividend; AGM on Aug 27, 2026
Alkem Laboratories recommended a final dividend of ₹10 per equity share for FY26. The company will hold its 52nd AGM on August 27, 2026, and has fixed August 7, 2026, as the record date for dividend payment. Mrs. Madhurima Singh's re-appointment as Executive Director was also approved.
The dividend recommendation and director re-appointment are positive developments, but the financial results themselves are not detailed in this snippet, limiting the immediate impact assessment.
The company is recommending a dividend and re-appointing a director, both positive indicators for shareholders.
Alkem Laboratories Limited announced the outcome of its Board Meeting held on 28th May, 2026. The Board has approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2026.
In addition, the Board has recommended a final dividend of ₹10 per equity share of ₹2 each for the financial year ended 31st March, 2026. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting (AGM).
The 52nd AGM of the Company is scheduled to be held on 27th August, 2026, with a cut-off date fixed as 20th August, 2026. The record date for the purpose of payment of the final dividend has been set as 07th August, 2026. If declared by the shareholders, the final dividend will be paid on and from 01st September, 2026.
Furthermore, the Board has approved the re-appointment of Mrs. Madhurima Singh as an Executive Director for a term of five consecutive years, effective from 20th December, 2026, up to 19th December, 2031, subject to shareholder approval. The auditors have expressed an unmodified opinion in the Audit Reports on the financial results.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.